Xtandi 40 MG tablet 120S
Ended Awarded Last action
- Contract number
- SPE2DR26FCRR9
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $17,021
Award facts
- Contract value 100% obligated
- $17,021.36 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $17,021.36 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xtandi 40 mg tablets (120 count). This delivery order, issued on December 29, 2025, with an ultimate completion date of December 30, 2025, utilizes firm fixed-price pricing and carries no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. The award is structured as a delivery order issued under DMS Pharmaceutical Group's Indefinite Delivery Contract (SPE2DR) within the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy that establishes multiple regional prime vendor contractors to supply pharmaceuticals and medical consumables to Department of Defense healthcare facilities worldwide.
DMS Pharmaceutical Group has maintained substantial federal contracting activity as a critical supplier within the military pharmaceutical supply chain since its SAM registration in 2001. The company's product portfolio encompasses branded and generic prescription medications, biologics, vaccines, and specialty pharmaceuticals, including oncology treatments such as Xtandi. The underlying PPV-G GEN V indefinite delivery contract, awarded to DMS Pharmaceutical Group on November 13, 2025, carries a ceiling value of $499,999,999 with an ultimate completion date of December 31, 2036, featuring a 30-month base period and three 30-month option periods. This contract structure enables the Defense Logistics Agency to issue firm fixed-price delivery orders for diverse pharmaceutical requirements supporting military healthcare operations globally.
Quick answers
Who was awarded contract SPE2DR26FCRR9?
SPE2DR26FCRR9 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 29, 2025.
How much is contract SPE2DR26FCRR9 worth?
The government has obligated $17,021 on SPE2DR26FCRR9.
Is contract SPE2DR26FCRR9 an order under another contract?
Yes. SPE2DR26FCRR9 is a delivery order under SPE2DR25D9168, an indefinite delivery contract.
Was contract SPE2DR26FCRR9 competed?
The extent of competition for SPE2DR26FCRR9 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award